Screener
Exelixis EXEL U.S. — Total revenues
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Exelixis’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q3 2026
- Accession
- 0000939767-26-000098
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| U.S. | $578,361 | $524,768 | $1,136,907 | $1,041,952 |
| Europe | 46,007 | 37,033 | 85,575 | 69,739 |
| Japan | 4,322 | 6,460 | 17,020 | 12,017 |
| Total revenues | $628,690 | $568,261 | $1,239,502 | $1,123,708 |
Item 1. Financial Statements.
FAQ
- What is Exelixis's U.S. — total revenues?
- Exelixis (EXEL) reported U.S. — total revenues of $578.36M in Q2 2026.
- How has Exelixis's U.S. — total revenues changed year-over-year?
- Exelixis's U.S. — total revenues increased by 10.2% year-over-year, from $524.77M to $578.36M.
- What is the long-term trend for Exelixis's U.S. — total revenues?
- Over 4 years (2021 to 2025), Exelixis's U.S. — total revenues has grown at a 18.4% compound annual growth rate (CAGR), from $1.09B to $2.14B.
- What does U.S. — total revenues mean?
- This metric represents the total gross revenue generated from the sale of pharmaceutical products and licensing arrangements within the United States market. It captures the primary income stream from the company's core oncology portfolio, reflecting market penetration and commercial success in the domestic region. This figure serves as a key indicator of the company's ability to monetize its clinical assets and maintain competitive positioning in the U.S. healthcare landscape.
Ask your AI about Exelixis's u.s. — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude